Assenagon Asset Management S.A. Lowers Position in The Cooper Companies, Inc. (NASDAQ:COO)

Assenagon Asset Management S.A. decreased its position in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 39.5% during the third quarter, according to its most recent filing with the SEC. The firm owned 323,982 shares of the medical device company’s stock after selling 211,927 shares during the period. Assenagon Asset Management S.A. owned about 0.16% of Cooper Companies worth $35,748,000 at the end of the most recent quarter.

Other institutional investors have also recently made changes to their positions in the company. Benjamin F. Edwards & Company Inc. raised its holdings in Cooper Companies by 248.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 244 shares of the medical device company’s stock worth $25,000 after purchasing an additional 174 shares in the last quarter. Innealta Capital LLC purchased a new position in Cooper Companies during the 2nd quarter valued at about $25,000. Covestor Ltd boosted its stake in Cooper Companies by 305.9% during the first quarter. Covestor Ltd now owns 276 shares of the medical device company’s stock worth $28,000 after acquiring an additional 208 shares in the last quarter. Crewe Advisors LLC grew its holdings in Cooper Companies by 286.4% in the second quarter. Crewe Advisors LLC now owns 340 shares of the medical device company’s stock worth $30,000 after purchasing an additional 252 shares during the period. Finally, Tortoise Investment Management LLC increased its stake in shares of Cooper Companies by 75.4% during the second quarter. Tortoise Investment Management LLC now owns 393 shares of the medical device company’s stock valued at $34,000 after purchasing an additional 169 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Analyst Ratings Changes

A number of brokerages have recently commented on COO. Wells Fargo & Company boosted their price target on Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Robert W. Baird increased their target price on Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, August 29th. Needham & Company LLC reaffirmed a “hold” rating on shares of Cooper Companies in a research report on Thursday, August 29th. Stifel Nicolaus reiterated a “buy” rating and issued a $115.00 price target (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Finally, Piper Sandler raised their price objective on shares of Cooper Companies from $115.00 to $120.00 and gave the company an “overweight” rating in a research note on Thursday, August 29th. Three investment analysts have rated the stock with a hold rating and ten have assigned a buy rating to the company’s stock. According to MarketBeat.com, Cooper Companies currently has a consensus rating of “Moderate Buy” and a consensus price target of $115.00.

Cooper Companies Trading Up 1.9 %

Shares of COO stock opened at $107.30 on Friday. The stock has a market capitalization of $21.37 billion, a P/E ratio of 63.12, a P/E/G ratio of 2.56 and a beta of 0.98. The company has a current ratio of 1.99, a quick ratio of 1.18 and a debt-to-equity ratio of 0.33. The firm’s 50 day moving average is $105.46 and its 200 day moving average is $96.66. The Cooper Companies, Inc. has a 12-month low of $75.93 and a 12-month high of $112.38.

Cooper Companies (NASDAQ:COO) last issued its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 EPS for the quarter, topping the consensus estimate of $0.91 by $0.05. The company had revenue of $1 billion during the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. Cooper Companies’s revenue was up 7.8% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.84 earnings per share. Research analysts expect that The Cooper Companies, Inc. will post 3.65 earnings per share for the current year.

Insider Activity

In related news, COO Daniel G. Mcbride sold 114,992 shares of the business’s stock in a transaction that occurred on Wednesday, September 4th. The shares were sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the sale, the chief operating officer now directly owns 44,696 shares in the company, valued at approximately $4,714,534.08. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. In other Cooper Companies news, CFO Brian G. Andrews sold 24,788 shares of the firm’s stock in a transaction that occurred on Thursday, September 5th. The shares were sold at an average price of $105.90, for a total transaction of $2,625,049.20. Following the sale, the chief financial officer now owns 6,614 shares in the company, valued at approximately $700,422.60. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, COO Daniel G. Mcbride sold 114,992 shares of the company’s stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total transaction of $12,129,356.16. Following the completion of the transaction, the chief operating officer now owns 44,696 shares of the company’s stock, valued at approximately $4,714,534.08. The trade was a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 256,373 shares of company stock valued at $27,637,427 in the last quarter. 2.00% of the stock is currently owned by insiders.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.